Celltrion is doing well in Japan, recording the top market share for cancer and rheumatoid arthritis drugs

In November, pharmaceutical company Celltrion's biosimilar breast and stomach cancer drug "Hojuma" (the active ingredient is trastuzumab) rose to 74% of the market share in Japan.
"Hojuma" has been expanding its market since it exceeded the share of original drugs for the first time in the April-June 2021 period. Celltrion's Japanese subsidiary is targeting companies with influence in the prescription field.
The sales method in which the local subsidiary and its partner distribution company each sell their products has also proved effective.
Under this strategy, the market share of the metastatic rectal cancer and breast cancer drug "Vexelma" (active ingredient: bevacizumab) also fell to 4.4% in November.
Compared to the same month last year, the share of biosimilar prescriptions rose to 23%, a three-fold increase. Although Vexelma is the most generic drug in Japan, it has risen to second place in terms of share of biosimilar prescriptions in just one year since its launch.
In addition, the rheumatoid arthritis treatment drug "Remsima" (the active ingredient is infliximab) and the autoimmune disease treatment drug "Eufleima" (the active ingredient is adalimumab) are both biosimilars.
The company has the largest market share in Japan. Going forward, the company plans to expand its lineup of pharmaceuticals for allergies, eye diseases, and other conditions.